Syndrome News and Research

RSS

Research suggests that Ginkgo biloba extract contains naturally occurring inhibitors against SARS-CoV-2

Researchers at Shihezi University in China found that Gingko Biloba leaves extract contains the most potent SARS-CoV-2 3-Chymotrypsin-like protease (3CLpro). This virally encoded main proteinase is essential for viral replication in coronaviruses.

27 Apr 2021

Study reveals a hidden role of circulating microRNA as a driver of SARS-CoV-2 infection

In a methodological tour-de-force study, a large group of researchers from the USA and the United Kingdom analyzed patient transcriptomic data in-depth and discovered a circulating microRNA (miR-2392) that is directly implicated in the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) machinery during the infection process.

26 Apr 2021

Study finds no evidence to support link between ABO blood group and COVID-19 risk

Researchers from the Boston University School of Public Health in the United States say there is no evidence to support a correlation between ABO blood group and the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or the severity of coronavirus disease 2019 (COVID-19).

26 Apr 2021

Prior SARS-CoV-2 infection and Pfizer-BioNTech’s COVID-19 vaccine provide similar immunity

Researchers in Israel have conducted a study showing that the immunity provided against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease (COVID-19) – is similar following natural infection or immunization with the Pfizer-BioNTech BNT162b2 vaccine.

26 Apr 2021

Study shows over 2% positivity rate for asymptomatic pediatric dental patients tested for COVID-19

A study by a University of Illinois Chicago pediatric dentist has shown a novel way to track potential COVID-19 cases -- testing children who visit the dentist. The study also showed an over 2% positivity rate for the asymptomatic children tested.

26 Apr 2021

Ultraviolet C radiation is effective in inactivating SARS-CoV-2 on glass surfaces, a study finds

A team of scientists from the Texas Biomedical Research Institute and UV Innovators, Inc., USA, recently developed an ultraviolet C radiation emitting device called NuvaWave, which is capable of inactivating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on glass surfaces within seconds.

26 Apr 2021

Researchers characterize India’s devastating second wave of COVID-19

The COVID-19 pandemic continues to take a heavy toll on human health worldwide. The second wave in India has caught everyone by surprise, showing up the total lack of foresight or precautions. With well over 0.2 million deaths in India, and infections raging out of control, a new study predicts 0.35 million daily cases at the peak of the second wave.

26 Apr 2021

SARS-CoV-2 antibody response robust in nursing home residents after Pfizer-BioNTech vaccine

However, with the waning of the immune response, it is not clear if these older people respond to the vaccine as well as younger individuals do. A recent study explored this question and found that though the antibody levels were somewhat lower in this group, they were still robust. This is a promising observation.

26 Apr 2021

Host cell transmembrane protein MARCH8 targets lysine residues to inhibit SARS-CoV-2 and other viruses

A new study deals with the inhibitory activity of a membrane protein that has broad-spectrum activity against multiple viruses, showing that this is due to its effect on cytoplasmic lysine residue incorporation into replicating virions.

26 Apr 2021

Could pooled testing really improve COVID-19 transmission management and decrease costs?

Pooled testing for SARS-CoV-2 detection is instrumental for increasing test capacity while decreasing test cost. A team of researchers at Yale School of the Environment determined the barriers to implementing pooled testing in United States laboratories. The study showed that many laboratories use many instruments in their testing procedures, varying in the number of samples each can process.

26 Apr 2021

Previous SARS-CoV-2 infection associated with more adverse events following mRNA vaccination

The phase 3 trials of the Pfizer and Moderna COVID-19 vaccines did not include those with a known previous SARS-CoV-2 infection. Recent evidence indicates that mRNA vaccines may induce more adverse events in these individuals. In a recent study, 947 individuals, 265 of which have previously reported SARS-CoV-2 infection, were monitored post-vaccination for adverse events, finding that there could be a link between previous infection and greater incidence of these events.

26 Apr 2021

Cleavage site recognition by SARS-CoV-2 main protease as new antiviral drug target

Many research groups have and are investigating main protease inhibitors as antiviral drugs, and in a paper recently uploaded to the bioRxiv* preprint server, a team of researchers examine the crystal structure of the protein while bound to various viral substrate peptides (P1-4). In doing so, they reveal the way in which the bound peptide sequence can direct and modulate enzyme activity, providing new templates towards antiviral drug design.

26 Apr 2021

Researchers examine potential SARS-CoV-2 antivirals using a drug repurposing library

A new study deals with the screening of the Drug Repurposing Hub (DRH) library for identifying small compounds which are capable of inhibiting SARS-CoV-2 using both in vitro and in vivo experimental studies. These molecules could be used for designing a novel therapeutic system against SARS-CoV-2 infection.

26 Apr 2021

Single dose of J&J's Ad26.COV2.S vaccine effective against SARS-CoV-2 including in South Africa variant

One of these vaccines, the Ad26.COV2.S vaccine by Johnson & Johnson and Janssen, is a recombinant, replication-incompetent human adenovirus type 26 vector that encodes full-length SARS-CoV-2 spike protein in a prefusion-stabilized conformation.

26 Apr 2021

Real-world study in India finds COVISHIELD vaccine safe and effective

New research led by Naresh Trehan of Medanta-The Medicity in India found the COVISHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccine) vaccine produced an immune response from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) two weeks after vaccination with limited side effects.

26 Apr 2021

SARS-CoV-2 limits type I and type III IFN protein biogenesis

New research led by Roy Parker of the University of Colorado Boulder finds that SARS-CoV-2 prevents the IFN response despite an increased presence of IFN-encoding mRNAs by suppressing transcriptional processes. Inhibition of IFN mRNAs triggers degradation from the activation of RNase L and the SARS-CoV-2 protein Nsp1.

26 Apr 2021

Recombinant protein vaccine fails expectations for SARS-CoV-2 neutralization

New interim results of a phase 1-2 clinical trial published in The Lancet Infectious Diseases tested the safety and effectiveness of an adjuvanted recombinant protein vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) called CoV2 preS dTM.

26 Apr 2021

Potential new COVID vaccine from Australia

Phase 1 trial results published in The Lancet Infectious Diseases found a new subunit vaccine —an MF59-adjuvanted subunit vaccine using recombinant spike glycoprotein stabilized in a prefusion conformation by a novel molecular clamp — targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was safe and effective in producing an antigen-specific response in healthy adults.

26 Apr 2021

The potential of CRISPR-based diagnostic assays and treatment approaches against COVID-19

In their review paper recently published in the Indian Journal of Clinical Biochemistry, a group of authors discusses currently available and forthcoming CRISPR-based diagnostic assays, as well as the possibility of using the CRISPR/Cas system as a salient treatment or prevention strategy in the fight against coronavirus disease 2019 (COVID-19).

25 Apr 2021

A detailed look at two cases of symptomatic COVID in vaccinated individuals

In a recent brief report published in the prestigious New England Journal of Medicine, researchers from the Rockefeller University in New York described a case of two fully vaccinated individuals in whom they found subsequent breakthrough infections with variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), carrying a number of substitutions of interest.

25 Apr 2021

Syndrome News and Research

Research suggests that Ginkgo biloba extract contains naturally occurring inhibitors against SARS-CoV-2

Study reveals a hidden role of circulating microRNA as a driver of SARS-CoV-2 infection

Study finds no evidence to support link between ABO blood group and COVID-19 risk

Prior SARS-CoV-2 infection and Pfizer-BioNTech’s COVID-19 vaccine provide similar immunity

Study shows over 2% positivity rate for asymptomatic pediatric dental patients tested for COVID-19

Ultraviolet C radiation is effective in inactivating SARS-CoV-2 on glass surfaces, a study finds

Researchers characterize India’s devastating second wave of COVID-19

SARS-CoV-2 antibody response robust in nursing home residents after Pfizer-BioNTech vaccine

Host cell transmembrane protein MARCH8 targets lysine residues to inhibit SARS-CoV-2 and other viruses

Could pooled testing really improve COVID-19 transmission management and decrease costs?

Previous SARS-CoV-2 infection associated with more adverse events following mRNA vaccination

Cleavage site recognition by SARS-CoV-2 main protease as new antiviral drug target

Researchers examine potential SARS-CoV-2 antivirals using a drug repurposing library

Single dose of J&J's Ad26.COV2.S vaccine effective against SARS-CoV-2 including in South Africa variant

Real-world study in India finds COVISHIELD vaccine safe and effective

SARS-CoV-2 limits type I and type III IFN protein biogenesis

Recombinant protein vaccine fails expectations for SARS-CoV-2 neutralization

Potential new COVID vaccine from Australia

The potential of CRISPR-based diagnostic assays and treatment approaches against COVID-19

A detailed look at two cases of symptomatic COVID in vaccinated individuals

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News